Analysis of Drug Use in Non-Ventilator Covid-19 Patients at Bangil Hospital
| Main Authors: | Triamyanti, Vincentina Yenny, Herawati, Fauna, Yulia, Rika |
|---|---|
| Format: | Article PeerReviewed application/pdf |
| Bahasa: | eng |
| Terbitan: |
Faculty of Pharmacy, Universitas Airlangga
, 2022
|
| Subjects: | |
| Online Access: |
http://repository.ubaya.ac.id/42228/ https://e-journal.unair.ac.id/JFIKI/article/view/35134 |
Daftar Isi:
- Background:Coronavirus Disease 2019 (Covid-19) is an infectious disease. Common signs and symptoms of Covid-19 infection include acute respiratory distress such as fever, cough and shortness of breath. Analysis of drug use in Non-Ventilator Covid-19 patientsneeds to be carried out to provide an overview of drug therapy currently being used based on the Covid-19 Management Guidelines Edition 3rdbecause so far, therehas not been a single type of drug that has received marketing authorization for Covid-19 therapy. Objectives: This study aims to determine patient profiles, therapeutic outcomes, suitability of drug use with Covid-19 Management Guidelines 3rdedition, the quantity of antibiotic use using the DDD/100 patient-days method and antivirals. Methods: The method used in this study is an observational design study which was analyzed descriptively with retrospective data collection. Result: Based on the profile of drug use in COVID-19 patients, there are 31 types of drug classes. The most consumed drugs were antibacterial (91%) and analgesics (91%), followed by vitamins (89%) and supplements (85%).Based on the DDD/100 patient-days value, the most widely used antibiotics were Azithromycin. Conclusion: The patient's profile at the time of admission to the hospital was 44% moderate and 56% severe. The condition of patients at the time of discharge from the hospital with a moderate degree using antivirals andantibiotics were more recovered and returned home with improvements with percentages of 84.1% and 88.64%, respectively.